Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 1 month ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
Findings from an Apolipoprotein B-Based Genetic Analysis
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,… View more
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 1 year ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 5 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 24: The KRAKEN Trial
Author(s): Stephen Nicholls Added: 5 months ago
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).KRAKEN is a phase 2, randomized, placebo-controlled trial… View more

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Professor of Pharmacology and Director of the Laboratory of Lipoprotein Metabolism of the Centre for the Study, Prevention and Therapy of Atherosclerosis
Job title: Director
PCSK9 Inhibition: The Big Step Forward in Lipid Control
Author(s): Rishi Rikhi , Michael D Shapiro Added: 1 year ago

Vascular Disease and Surgery

Prevention & Chronic Conditions